Development of Antibody-Directed Therapies: Quo Vadis?
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Rodrigues, Tiago
Bernardes, Gonçalo JL https://orcid.org/0000-0001-6594-8917
Abstract
Less is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.
Description
Keywords
anti-tumor agents, antibody-drug conjugates, bioconjugation, drug delivery, linkers, Animals, Breast Neoplasms, Bystander Effect, Cell Line, Tumor, Drug Liberation, Female, Humans, Immunoconjugates, Mice, Neoplasms, Oligopeptides, Transplantation, Heterologous
Journal Title
Angew Chem Int Ed Engl
Conference Name
Journal ISSN
1433-7851
1521-3773
1521-3773
Volume Title
57
Publisher
Wiley
Publisher DOI
Sponsorship
Engineering and Physical Sciences Research Council (EP/M003647/1)
The Royal Society (uf110046)
European Research Council (676832)
European Commission (EC) (852985)
The Royal Society (uf110046)
European Research Council (676832)
European Commission (EC) (852985)